Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026)
Assembly Biosciences (ASMB) recorded quarterly Income from Continuing Operations of 9079000.0 in Q1 2026, down 141.1% quarter-over-quarter from 22090000.0 in Q4 2025, and down 2.96% on a YoY basis from 9355921.7 in Q1 2025.
Assembly Biosciences (ASMB) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Assembly Biosciences' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 9079000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 2.96% year-over-year to 9079000.0; the TTM figure through Mar 2026 stood at 6383000.0 (up 84.01% YoY), while the FY2025 annual figure was 6122000.0, up 84.76% from the prior year.
- Income from Continuing Operations was 9079000.0 for Q1 2026 at Assembly Biosciences, down from 22090000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 22090000.0 in Q4 2025 to a low of 24461000.0 in Q2 2022.
- Historically, Income from Continuing Operations has averaged 12335176.47 across 5 years, with a median of 10962000.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations fell 23.09% in 2022, then surged 313.74% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 22395000.0 in 2022, then jumped by 51.05% to 10962000.0 in 2023, then rose by 5.72% to 10335000.0 in 2024, then jumped by 313.74% to 22090000.0 in 2025, then slumped by 141.1% to 9079000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 9079000.0 (Q1 2026), 22090000.0 (Q4 2025), and 9196000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Assembly Biosciences | 418.96 Mn | 192.36 Mn | - | -9.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.08 Mn |
| Dec 31, 2025 | 22.09 Mn |
| Sep 30, 2025 | -9.20 Mn |
| Jun 30, 2025 | -10.20 Mn |
| Mar 31, 2025 | -8.82 Mn |
| Dec 31, 2024 | -10.34 Mn |
| Sep 30, 2024 | -9.61 Mn |
| Jun 30, 2024 | -11.15 Mn |
| Mar 31, 2024 | -9.08 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -14.42 Mn |
| Jun 30, 2023 | -16.90 Mn |
| Mar 31, 2023 | -18.95 Mn |
| Dec 31, 2022 | -22.40 Mn |
| Sep 30, 2022 | -23.15 Mn |
| Jun 30, 2022 | -24.46 Mn |
| Mar 31, 2022 | -23.09 Mn |
| Dec 31, 2021 | -62.79 Mn |
| Sep 30, 2021 | -18.80 Mn |
| Jun 30, 2021 | -23.60 Mn |